Optimizing autologous cell grafts to improve stem cell gene therapy

Experimental Hematology

Volumn 44, Issue 7, 2016, Pages 528-539

  Psatha, Nikoletta ^a,b   Karponi, Garyfalia ^a   Yannaki, Evangelia ^a,b  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CD34+ CELL; CELL COUNT; CELL EXPANSION; CELL FATE; CELL HOMING; CELL POPULATION; CELL RENEWAL; CELL TRANSFORMATION; CLINICAL EFFECTIVENESS; CORD BLOOD STEM CELL TRANSPLANTATION; ENGRAFTMENT; EX VIVO STUDY; GENETIC DISORDER; GENETIC ENGINEERING; HEMATOPOIETIC STEM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL GENE THERAPY; TREATMENT RESPONSE; ANIMAL; AUTOTRANSPLANTATION; CELL CULTURE TECHNIQUE; CELL DIFFERENTIATION; CELL MOTION; CELL PROLIFERATION; CYTOLOGY; DRUG DEVELOPMENT; DRUG EFFECTS; GENE THERAPY; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; PROCEDURES; SIGNAL TRANSDUCTION; STANDARDS; STEM CELL; STEM CELL TRANSPLANTATION;

ANIMALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; DRUG DISCOVERY; GENETIC ENGINEERING; GENETIC THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; SIGNAL TRANSDUCTION; STEM CELL TRANSPLANTATION; STEM CELLS; TRANSDUCTION, GENETIC; TRANSPLANTATION, AUTOLOGOUS;

EID: 84971595064     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2016.04.007     Document Type: Review

References (146)

1. Peters C., Steward C.G. Hematopoietic cell transplantation for inherited metabolic diseases: An overview of outcomes and practice guidelines. Bone Marrow Transplant 2003, 31:229-239.
2. King A., Shenoy S. Evidence-based focused review of the status of hematopoietic stem cell transplantation as treatment of sickle cell disease and thalassemia. Blood 2014, 123:3089-3094. quiz 3210.
3. Cavazzana-Calvo M., Hacein-Bev S., de Saint Basile G., et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
4. Cartier N., Hacein-Bey-Abina S., Bartholomae C.C., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326:818-823.
5. Aiuti A., Cattaneo F., Galimberti S., et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med 2009, 360:447-458.
6. Cavazzana-Calvo M., Payen E., Negre O., et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 2010, 467:318-322.
7. Biffi A., Montini E., Lorioli L., et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 2013, 341:1233158.
8. Aiuti A., Biasco L., Scarmuzzo S., et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science 2013, 341:1233151.
9. Wagner J.E., Barker J.N., DeFor T.E., et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: Influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002, 100:1611-1618.
10. Gluckman E., Rocha V., Boyer-Chammard A., et al. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. Outcome of cord-blood transplantation from related and unrelated donors. N Engl J Med 1997, 337:373-381.
11. Dorrell C., Gan O.I., Pereira D.S., Hawley R.G., Dick J.E. Expansion of human cord blood CD34(+)CD38(-) cells in ex vivo culture during retroviral transduction without a corresponding increase in SCID repopulating cell (SRC) frequency: Dissociation of SRC phenotype and function. Blood 2000, 95:102-110.
12. Grez M., Reichenbach J., Schwäble J., Seger R., Dinauer M.C., Thrasher A.J. Gene therapy of chronic granulomatous disease: The engraftment dilemma. Mol Ther 2011, 19:28-35.
13. Kang H.J., Bartholomae C.C., Paruzynski A., et al. Retroviral gene therapy for X-linked chronic granulomatous disease: Results from phase I/II trial. Mol Ther 2011, 19:2092-2101.
14. Hargrove P.W., Kepes S., Hanawa H., et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 2008, 16:525-533.
15. Urbinati F., Arumugam P., Higashimoto T., et al. Mechanism of reduction in titers from lentivirus vectors carrying large inserts in the 3'LTR. Mol Ther 2009, 17:1527-1536.
16. Emery D.W., Yannaki E., Tubb J., Nishino T., Li Q., Stamatoyannopoulos G. Development of virus vectors for gene therapy of beta chain hemoglobinopathies: Flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood 2002, 100:2012-2019.
17. Ramezani A., Hawley T.S., Hawley R.G. Performance- and safety-enhanced lentiviral vectors containing the human interferon-beta scaffold attachment region and the chicken beta-globin insulator. Blood 2003, 101:4717-4724.
18. Walters M.C., Rasko J., Hongeng S., et al. Update of results from the Northstar study (HGB-204): A phase 1/2 study of gene therapy for beta-thalassemia major via transplantation of autologous hematopoietic stem cells transduced ex-vivo with a lentiviral beta AT87Q-globin vector (LentiGlobin BB305). Blood 2015, 126:201.
19. Szilvassy S.J., Meyerrose T.E., Ragland P.L., Grimes B. Homing and engraftment defects in ex vivo expanded murine hematopoietic cells are associated with downregulation of beta1 integrin. Exp Hematol 2001, 29:1494-1502.
20. Ahmed F., Ings S.J., Pizzey A.R., et al. Impaired bone marrow homing of cytokine-activated CD34+ cells in the NOD/SCID model. Blood 2004, 103:2079-2087.
21. Mazurier F., Gan O.I., McKenzie J.L., Doedens M., Dick J.E. Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. Blood 2004, 103:545-552.
22. + cells. Br J Haematol 2002, 119:500-509.
23. Liu B., Buckley S.M., Lewis I.D., Goldman A.I., Wagner J.E., van der Loo J.C. Homing defect of cultured human hematopoietic cells in the NOD/SCID mouse is mediated by Fas/CD95. Exp Hematol 2003, 31:824-832.
24. Shpall E.J., Quinones R., Giller R., et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002, 8:368-376.
25. De Lima M., McMannis J., Gee A., et al. Transplantation of ex vivo expanded cord blood cells using the copper chelator tetraethylenepentamine: A phase I/II clinical trial. Bone Marrow Transplant 2008, 41:771-778.
26. Delaney C., Heimfeld S., Brashem-Stein C., Voorhies H., Manger R.L., Bernstein I.D. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010, 16:232-236.
27. Zhang C.C., Kaba M., Iizuka S., Huynh H., Harvey F. Angiopoietin-like 5 and IGFBP2 stimulate ex vivo expansion of human cord blood hematopoietic stem cells as assayed by NOD/SCID transplantation. Blood 2009, 111:3415-3423.
28. + cells in the NOD/SCID mouse model. Exp Hematol 2006, 34:433-442.
29. Sadelain M., Riviere I., Wang X., et al. Strategy for a multicenter phase I clinical trial to evaluate globin gene transfer in beta-thalassemia. Ann NY Acad Sci 2010, 1202:52-58.
30. Yannaki E., Emery D.W., Stamatoyannopoulos G. Gene therapy for β-thalassaemia: The continuing challenge. Expert Rev Mol Med 2010, 12:e31.
31. To L.B., Haylock D.N., Simmons P.J., Juttner C.A. The biology and clinical uses of blood stem cells. Blood 1997, 89:2233-2258.
32. Champlin R.E., Schmitz N., Horowitz M.M., et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000, 95:3702-3709.
33. Bensinger W.I., Martin P.J., Storer B., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
34. Gratwohl A., Baldomero H., Frauendorfer K., et al. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: Focus on the use of cord blood products. Bone Marrow Transplant 2008, 41:687-705.
35. Guenechea G., Gan O.I., Dorrell C., Dick J.E. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol 2001, 2:75-82.
36. McKenzie J.L., Gan O.I., Doedens M., Wang J.C.Y., Dick J.E. Individual stem cells with highly variable proliferation and self-renewal properties comprise the human hematopoietic stem cell compartment. Nat Immunol 2006, 7:1225-1233.
37. Majeti R., Park C.Y., Weissman I.L. Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood. Cell Stem Cell 2007, 1:635-645.
38. Doulatov S., Notta F., Laurenti E., Dick J.E. Hematopoiesis: A human perspective. Cell Stem Cell 2012, 10:120-136.
39. Notta F., Doulatov S., Laurenti E., Poeppl A., Jurisica I., Dick J.E. Isolation of single human hematopoietic stem cells capable of long-term multilineage engraftment. Science 2011, 333:218-221.
40. Chen J.Y., Miyanishi M., Wang S.K., et al. Hoxb5 marks long-term haematopoietic stem cells and reveals a homogenous perivascular niche. Nature 2016, 530:223-227.
41. Baldwin K., Urbinati F., Romero Z., et al. Enrichment of human hematopoietic stem/progenitor cells facilitates transduction for stem cell gene therapy. Stem Cells 2015, 33:1532-1542.
42. Brendel C., Goebel B., Daniela A., et al. CD133-targeted gene transfer into long-term repopulating hematopoietic stem cells. Mol Ther 2015, 23:63-70.
43. Fruehauf S., Veldwijk M.R., Seeger T., et al. A combination of granulocyte-colony-stimulating factor (G-CSF) and plerixafor mobilizes more primitive peripheral blood progenitor cells than G-CSF alone: Results of a European phase II study. Cytotherapy 2009, 11:992-1001.
44. + cell subclasses and lymphocyte subsets in blood grafts collected after various mobilization methods in myeloma patients. Transfusion 2013, 53:1024-1032.
45. Varmavuo V., Mäntymaa P., Nousiainen T., Valonen P., Kuittinen T., Jantunen E. Blood graft composition after plerixafor injection in patients with NHL. Eur J Haematol 2012, 89:128-135.
46. Yannaki E., Karponi G., Zerrvou F., et al. Hematopoietic stem cell mobilization for gene therapy: Superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major. Hum Gene Ther 2013, 24:852-860.
47. Psatha N., Sgouramali E., Gkountis A., et al. Superior long-term repopulating capacity of G-CSF + plerixafor-mobilized blood: implications for stem cell gene therapy by studies in the Hbb(th-3) mouse model. Hum Gene Ther Methods 2014, 25:317-327.
48. + cells represent an optimal graft source for thalassemia gene therapy. Blood 2015, 126:616-619.
49. Genovese P., Schiroli G., Escobar G., et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature 2014, 510:235-240.
50. Bhatia M., Bonnet D., Kapp U., Wang J.C., Murdoch B., Dick J.E. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J Exp Med 1997, 186:619-624.
51. Ueda T., Tsuji K., Yoshino H., et al. Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor. J Clin Invest 2000, 105:1013-1021.
52. Jaroscak J., Goltry K., Smith A., et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo-expanded UCB cells: Results of a phase 1 trial using the AastromReplicell System. Blood 2003, 101:5061-5067.
53. Robinson S.N., Ng J., Niu T., et al. Superior ex vivo cord blood expansion following co-culture with bone marrow-derived mesenchymal stem cells. Bone Marrow Transplant 2006, 37:359-366.
54. Yamaguchi M., Hirayama F., Kanai M., et al. Serum-free coculture system for ex vivo expansion of human cord blood primitive progenitors and SCID mouse-reconstituting cells using human bone marrow primary stromal cells. Exp Hematol 2001, 29:174-182.
55. + human universal stromal feeder layer to expand/maintain human bone marrow hematopoietic stem/progenitor cells in a serum-free culture system. Exp Hematol 2006, 34:1353-1359.
56. Khoury M., Drake A., Chen Q., et al. Mesenchymal stem cells secreting angiopoietin-like-5 support efficient expansion of human hematopoietic stem cells without compromising their repopulating potential. Stem Cells Dev 2011, 20:1371-1381.
57. Walenda T., Bokermann G., Ventura Ferreira M.S., et al. Synergistic effects of growth factors and mesenchymal stromal cells for expansion of hematopoietic stem and progenitor cells. Exp Hematol 2011, 39:617-628.
58. Dexter T.M., Moore M.A., Sheridan A.P. Maintenance of hemopoietic stem cells and production of differentiated progeny in allogeneic and semiallogeneic bone marrow chimeras in vitro. J Exp Med 1977, 147:1612-1616.
59. Lewis I.D., Verfaillie C.M. Multi-lineage expansion potential of primitive hematopoietic progenitors: Superiority of umbilical cord blood compared to mobilized peripheral blood. Exp Hematol 2000, 28:1087-1095.
60. Chou S., Lodish H.F. Fetal liver hepatic progenitors are supportive stromal cells for hematopoietic stem cells. Proc Natl Acad Sci USA 2010, 107:7799-7804.
61. Moore K.A., Ema H., Lemischka I.R. In vitro maintenance of highly purified, transplantable hematopoietic stem cells. Blood 1997, 89:4337-4347.
62. Klein C., Strobel J., Zingsem J., et al. Ex vivo expansion of hematopoietic stem- and progenitor cells from cord blood in coculture with mesenchymal stroma cells from amnion, chorion, Wharton's jelly, amniotic fluid, cord blood, and bone marrow. Tissue Eng Part A 2013, 19:2577-2585.
63. Chute J.P., Muramoto G., Fung J., Oxford C. Quantitative analysis demonstrates expansion of SCID-repopulating cells and increased engraftment capacity in human cord blood following ex vivo culture with human brain endothelial cells. Stem Cells 2004, 22:202-215.
64. Tzeng Y.S., Li H., Kang Y.L., Chen W.C., Cheng W.C., Lai D.M. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood 2011, 117:429-439.
65. Andrade P.Z., dos Santos F., Almeida-Porada G., da Silva C.L., Cabral J.M. Systematic delineation of optimal cytokine concentrations to expand hematopoietic stem/progenitor cells in co-culture with mesenchymal stem cells. Mol Biosyst 2010, 6:1207-1215.
66. Broxmeyer H.E., Cooper S., Hass D.M., Hathaway J.K., Stehman F.B., Hangoc G. Experimental basis of cord blood transplantation. Bone Marrow Transplant 2009, 44:627-633.
67. Levac K., Karanu F., Bhatia M. Identification of growth factor conditions that reduce ex vivo cord blood progenitor expansion but do not alter human repopulating cell function in vivo. Haematologica 2005, 90:166-172.
68. - cells with preserved ability to engraft SCID-hu bone. Blood 1998, 91:1206-1215.
69. + cells into rapid division. Exp Hematol 1999, 27:1019-1028.
70. Nikougoftar Zarif M., Soleimani M., Abolghasemi H., Amirizade N., Abroun S., Kaviani S. The high yield expansion and megakaryocytic differentiation of human umbilical cord blood CD133(+) cells. Cell J 2011, 13:173-178.
71. Zhang C.C., Kaba M., Ge G., et al. Angiopoietin-like proteins stimulate ex vivo expansion of hematopoietic stem cells. Nat Med 2006, 12:240-245.
72. Kawano Y., Kobune M., Yamaguchi M., et al. Ex vivo expansion of human umbilical cord hematopoietic progenitor cells using a coculture system with human telomerase catalytic subunit (hTERT)-transfected human stromal cells. Blood 2003, 101:532-540.
73. De Lima M., McNiece I., Robinson S.N., et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012, 367:2305-2315.
74. Chute J.P. Ex vivo culture with human brain endothelial cells increases the SCID-repopulating capacity of adult human bone marrow. Blood 2002, 100:4433-4439.
75. Rafii S., Shapiro F., Pettengell R., et al. Human bone marrow microvascular endothelial cells support long-term proliferation and differentiation of myeloid and megakaryocytic progenitors. Blood 1995, 86:3353-3363.
76. Li N., Eljaafari A., Bensoussan D., et al. Human umbilical vein endothelial cells increase ex vivo expansion of human CD34(+) PBPC through IL-6 secretion. Cytotherapy 2006, 8:335-342.
77. Seandel M., Butler J.M., Kobayashi H., et al. Generation of a functional and durable vascular niche by the adenoviral E4ORF1 gene. Proc Natl Acad Sci USA 2008, 105:19288-19293.
78. Butler J.M., Nolan D.J., Vertes E.L., et al. Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 2010, 6:251-264.
79. Butler J.M., Gars E.J., James D.J., Nolan D.J., Scandura J.M., Rafii S. Development of a vascular niche platform for expansion of repopulating human cord blood stem and progenitor cells. Blood 2012, 120:1344-1347.
80. Kobayashi H., Butler J.M., O'Donnell R., et al. Angiocrine factors from Akt-activated endothelial cells balance self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol 2010, 12:1046-1056.
81. Perkins A.C., Cory S. Conditional immortalization of mouse myelomonocytic, megakaryocytic and mast cell progenitors by the Hox-2.4 homeobox gene. EMBO J 1993, 12:3835-3846.
82. + subpopulations of human bone marrow cells. Proc Natl Acad Sci USA 1994, 91:12223-12227.
83. Sauvageau G., Thorsteinsdottir U., Eaves C.J., et al. Overexpression of HOXB4 in hematopoietic cells causes the selective expansion of more primitive populations in vitro and in vivo. Genes Dev 1995, 9:1753-1765.
84. + cells, but impairs lymphomyeloid differentiation. Blood 2003, 101:1759-1768.
85. Krosl J., Austin P., Beslu N., Kroon E., Humphries R.K., Sauvageau G. In vitro expansion of hematopoietic stem cells by recombinant TAT-HOXB4 protein. Nat Med 2003, 9:1428-1432.
86. Amsellem S., Pflumio F., Bardinet D., et al. Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein. Nat Med 2003, 9:1423-1427.
87. Huang X., Lee M.R., Cooper S., et al. Activation of OCT4 enhances ex vivo expansion of human cord blood hematopoietic stem and progenitor cells by regulating HOXB4 expression. Leukemia 2016, 20:144-153.
88. Ohta H., Sekulovic S., Bakovic S., et al. Near-maximal expansions of hematopoietic stem cells in culture using NUP98-HOX fusions. Exp Hematol 2007, 35:817-830.
89. Abraham A., Kim Y.S., Zhao H., Humphries K., Persons D.A. Increased engraftment of human short term repopulating hematopoietic cells in NOD/SCID/IL2rγnull mice by lentiviral expression of NUP98-HOXA10HD. PLoS One 2016, 11:e0147059.
90. Zhang J., Tam W.L., Tong G.Q., et al. Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1. Nat Cell Biol 2006, 8:1114-1123.
91. Yang J., Aguila J.R., Alipio Z., Lai R., Fink L.M., Ma Y. Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4. J Hematol Oncol 2011, 4:38.
92. Aguila J.R., Liao W., Yang J., et al. SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. Blood 2011, 118:576-585.
93. Ma Y., Cui W., Yang J., et al. SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic mice. Blood 2006, 108:2726-2735.
94. Li A., Yang Y., Gao C., et al. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. J Clin Invest 2013, 123:4195-4207.
95. Milanovich S., Peterson J., Allred J., et al. Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol 2015, 43. 53-64.e1-8.
96. Piacibello W., Sanavio F., Garetto L., et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997, 89:2644-2653.
97. De Graaf C.A., Metcalf D. Thrombopoietin and hematopoietic stem cells. Cell Cycle 2011, 10:1582-1589.
98. Nagasawa Y., Wood B.L., Wang L., et al. Anatomical compartments modify the response of human hematopoietic cells to a mitogenic signal. Stem Cells 2006, 24:908-917.
99. Neff T., Horn P.A., Valli V.E., et al. Pharmacologically regulated in vivo selection in a large animal. Blood 2002, 100:2026-2031.
100. Richard R.E., Wood B., Zeng H., Jin L., Papayannopoulou T., Blau C.A. Expansion of genetically modified primary human hemopoietic cells using chemical inducers of dimerization. Blood 2000, 95:430-436.
101. Okazuka K., Beard B.C., Emery D.W., et al. Long-term regulation of genetically modified primary hematopoietic cells in dogs. Mol Ther 2011, 19:1287-1294.
102. Abdel-Azim H., Zhu Y., Hollis R., et al. Expansion of multipotent and lymphoid-committed human progenitors through intracellular dimerization of Mpl. Blood 2008, 111:4064-4074.
103. Artavanis-Tsakonas S., Rand M.D., Lake R.J. Notch signaling: Cell fate control and signal integration in development. Science 1999, 284:770-776.
104. Kojika S., Griffin J.D. Notch receptors and hematopoiesis. Exp Hematol 2001, 29:1041-1052.
105. Karanu F.N., Murdoch B., Gallacher L., et al. The notch ligand jagged-1 represents a novel growth factor of human hematopoietic stem cells. J Exp Med 2000, 192:1365-1372.
106. Varnum-Finney B., Wu L., Yu M., et al. Immobilization of Notch ligand, Delta-1, is required for induction of notch signaling. J. Cell Sci 2000, 113(Pt 23):4313-4318.
107. Varnum-Finney B. Combined effects of Notch signaling and cytokines induce a multiple log increase in precursors with lymphoid and myeloid reconstituting ability. Blood 2002, 101:1784-1789.
108. - cord blood cells. J Clin Invest 2002, 110:1165-1174.
109. Delaney C., Varnum-Finney B., Aoyama K., Brashem-Stein C., Bernstein I.D. Dose-dependent effects of the Notch ligand Delta1 on ex vivo differentiation and in vivo marrow repopulating ability of cord blood cells. Blood 2005, 106:2693-2699.
110. Milhem M., Mahmud N., Lavelle D., et al. Modification of hematopoietic stem cell fate by 5aza 2'deoxycytidine and trichostatin A. Blood 2004, 103:4102-4110.
111. Mahmud N., Petro B., Baluchamy S., et al. Differential effects of epigenetic modifiers on the expansion and maintenance of human cord blood stem/progenitor cells. Biol. Blood Marrow Transplant 2014, 20:480-489.
112. Saraf S., Araki H., Petro B., et al. Ex vivo expansion of human mobilized peripheral blood stem cells using epigenetic modifiers. Transfusion 2015, 55:864-874.
113. Chaurasia P., Gajzer D.C., Schaniel C., Souza S.D., Hoffman R. Epigenetic reprogramming induces the expansion of cord blood stem cells. J Clin Invest 2014, 124:2378-2395.
114. Gul H., Marquez-Curtis L.A., Jahroudi N., Lo J., Turner A.R., Janowska-Wieczorek A. Valproic acid increases CXCR4 expression in hematopoietic stem/progenitor cells by chromatin remodeling. Stem Cells Dev 2009, 18:831-838.
115. Peled T., Shoham H., Aschengrau D., et al. Nicotinamide, a SIRT1 inhibitor, inhibits differentiation and facilitates expansion of hematopoietic progenitor cells with enhanced bone marrow homing and engraftment. Exp Hematol 2012, 40:342-355.e1.
116. Horwitz M.E., Chao N.J., Rizzieri D.A., et al. Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment. J Clin Invest 2014, 124:3121-3128.
117. Peled T., Landau E., Mandel J., et al. Linear polyamine copper chelator tetraethylenepentamine augments long-term ex vivo expansion of cord blood-derived CD34+ cells and increases their engraftment potential in NOD/SCID mice. Exp Hematol 2004, 32:547-555.
118. Boitano A.E., Wang J., Romeo R., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010, 329:1345-1348.
119. Wagner J.E., Brunstein C.G., Boitano A.E., et al. Phase I/II trial of stemregenin-1 expanded umbilical cord blood hematopoietic stem cells supports testing as a stand-alone graft. Cell Stem Cell 2016, 18:144-155.
120. Fares I., Chagraoui J., Gareau Y., et al. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. Science 2014, 345:1509-1512.
121. Csaszar E., Kirouac D.C., Yu M., et al. Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. Cell Stem Cell 2012, 10:218-229.
122. Chen X., Skutt-Kakaria K., Davison J., et al. G9a/GLP-dependent histone H3K9me2 patterning during human hematopoietic stem cell lineage commitment. Genes Dev 2012, 26:2499-2511.
123. Hidalgo A., Weiss L.A., Frenette P.S. Functional selectin ligands mediating human CD34(+) cell interactions with bone marrow endothelium are enhanced postnatally. J Clin Invest 2002, 110:559-569.
124. Xia L., McDaniel J.M., Yago T., Doeden A., McEver R.P. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004, 104:3091-3096.
125. Robinson S.N., Simmons P.J., Thomas M.W., et al. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγ(null) mice. Exp Hematol 2012, 40:445-456.
126. Robinson S.N., Thomas M.W., Simmons P.J., et al. Fucosylation with fucosyltransferase VI or fucosyltransferase VII improves cord blood engraftment. Cytotherapy 2014, 16:84-89.
127. Popat U., Mehta R.S., Rezvani K., et al. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 2015, 125:2885-2892.
128. Jiang Y., Bonig H., Ulyanova T., Chang K., Papayannopoulou T. On the adaptation of endosteal stem cell niche function in response to stress. Blood 2009, 114:3773-3782.
129. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
130. North T.E., Goessling W., Walkley C.R., et al. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature 2007, 447:1007-1011.
131. Hoggatt J., Singh P., Sampath J., Pelus L.M. Prostaglandin E2 enhances hematopoietic stem cell homing, survival, and proliferation. Blood 2009, 113:5444-5455.
132. Pelus L.M., Hoggatt J., Singh P. Pulse exposure of haematopoietic grafts to prostaglandin E2 in vitro facilitates engraftment and recovery. Cell Prolif 2011, 44(Suppl 1):22-29.
133. Goessling W., Allen R.S., Guan X., et al. Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 2011, 8:445-458.
134. Hoggatt J., Mohammad K., Singh P., Pelus L.M. Prostaglandin E2 enhances long-term repopulation but does not permanently alter stem cell competiveness. Blood 2013, 122:2997-3000.
135. Cutler C., Multani P., Robbins D., et al. Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation. Blood 2013, 122:3074-3081.
136. Christopherson K.W., Hangoc G., Mantel C.R., Broxmeyer H.E. Modulation of hematopoietic stem cell homing and engraftment by CD26. Science 2004, 305:1000-1003.
137. - human umbilical cord blood donor hematopoietic stem cells/hematopoietic progenitor cells improves long-term engraftment into NOD/SCID/Beta2null immunodeficient mice. Stem Cells Dev 2007, 16:355-360.
138. Peranteau W.H., Endo M., Adibe O.O., Merchant A., Zoltick P.W., Flake A.W. CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. Blood 2006, 108:4268-4274.
139. + cells enhances their engraftment of nonobese diabetic/severe combined immunodeficiency mice. Stem Cells Dev 2007, 16:347-354.
140. Broxmeyer H.E., Pelus L.M. Inhibition of DPP4/CD26 and dmPGE2 treatment enhances engraftment of mouse bone marrow hematopoietic stem cells. Blood Cells Mol Dis 2014, 53:34-38.
141. Farag S.S., Srivastava S., Messina-Graham S., et al. In vivo DPP-4 inhibition to enhance engraftment of single-unit cord blood transplants in adults with hematological malignancies. Stem Cells Dev 2013, 22:1007-1015.
142. Holyoake T.L., Nicolini F.E., Eaves C.J. Functional differences between transplantable human hematopoietic stem cells from fetal liver, cord blood, and adult marrow. Exp Hematol 1999, 27:1418-1427.
143. Mayani H. Biological differences between neonatal and adult human hematopoietic stem/progenitor cells. Stem Cells Dev 2010, 19:285-298.
144. Tanavde V.M., Malehorn M.T., Lumkul R., et al. Human stem-progenitor cells from neonatal cord blood have greater hematopoietic expansion capacity than those from mobilized adult blood. Exp Hematol 2002, 30:816-823.
145. Holyoake T.L., Alcorn M.J., Richmond L., et al. CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transplant 1997, 19:1095-1101.
146. Tisdale J.F., Hanazono Y., Sellers S.E., et al. Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. Blood 1998, 92:1131-1141.